Stryker Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $25.8B+14.3% YoYTTM through 30 Jun 2026
Net Income $3.7B+24.6% YoYTTM through 30 Jun 2026
Free Cash Flow $4.7BTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 65.0% |
| EBITDA Margin | 27.7% |
| Operating Margin | 21.4% |
| Net Margin | 14.4% |
Returns
15.5%ROE
7.8%ROA
10.5%ROIC
Balance Sheet Health
Debt / Equity0.62x
Current Ratio2.16x
Net Debt$11.6B
Cash & Equivalents$3.4B
Quality Metrics
Altman Z-Score4.40
Piotroski F-Score8 / 9
FCF Margin18.2%
Rule of 4023.8
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $25.1B
Diluted EPS$9.65TTMFY2025: $8.40
Dividend
$1.76Per share, FY20260.64%Yield-7.4%5-yr growth
Capital Allocation
R&D Spend$1.7B
Capex Intensity3.2%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| MedSurg and Neurotechnology | $15.6B | +15.7% | |
| Orthopaedics | $9.5B | +4.3% |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.